Literature DB >> 9663791

Power and sample size for survival analysis under the Weibull distribution when the whole lifespan is of interest.

M Heo1, M S Faith, D B Allison.   

Abstract

Accessible and readily utilized software, tables and approximation formulae have been developed to estimate power and sample size for studies of time to event (survival times) when the survival times are assumed to be exponential. These methods can markedly misestimate power when the distribution is Weibull and not exponential. The Weibull distribution with increasing hazard is common in aging research, especially when the whole life span of the subjects is of interest. This note considers an extension of power and sample size calculations, previously developed under the exponential distributional assumption, to the more general case of the Weibull distribution for a prospective comparative follow-up study. The hypotheses are defined in terms of the ratio of the median survival times between two groups. It is shown that the power and sample sizes are heavily dependent on the shape parameter of the Weibull distribution. Using the extensions developed, investigators can use existing software and tables to calculate power and sample size under the assumption of a Weibull distribution.

Mesh:

Year:  1998        PMID: 9663791     DOI: 10.1016/s0047-6374(98)00010-4

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  7 in total

Review 1.  TOR signaling never gets old: aging, longevity and TORC1 activity.

Authors:  Daniel S Evans; Pankaj Kapahi; Wen-Chi Hsueh; Lutz Kockel
Journal:  Ageing Res Rev       Date:  2010-04-10       Impact factor: 10.895

2.  Group Sequential Design for Randomized Phase III Trials under the Weibull Model.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  J Biopharm Stat       Date:  2014-10-16       Impact factor: 1.051

3.  Power and sample size for randomized phase III survival trials under the Weibull model.

Authors:  Jianrong Wu
Journal:  J Biopharm Stat       Date:  2015       Impact factor: 1.051

4.  Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.

Authors:  Kim Jachno; Stephane Heritier; Rory Wolfe
Journal:  BMC Med Res Methodol       Date:  2019-05-16       Impact factor: 4.615

5.  Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects.

Authors:  Adam C Palmer; Peter K Sorger; Deborah Plana; Geoffrey Fell; Brian M Alexander
Journal:  Nat Commun       Date:  2022-02-15       Impact factor: 17.694

6.  A practical simulation method to calculate sample size of group sequential trials for time-to-event data under exponential and Weibull distribution.

Authors:  Zhiwei Jiang; Ling Wang; Chanjuan Li; Jielai Xia; Hongxia Jia
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

7.  Assessing accuracy of Weibull shape parameter estimate from historical studies for subsequent sample size calculation in clinical trials with time-to-event outcome.

Authors:  Milind A Phadnis; Palash Sharma; Nadeesha Thewarapperuma; Prabhakar Chalise
Journal:  Contemp Clin Trials Commun       Date:  2020-02-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.